Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial

(2014) Georg Hopfinger et al.   ANNALS OF HEMATOLOGY

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

(2014) S. M. Horwitz et al.   BLOOD

Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient

(2014) Alessandro Broccoli et al.   Clinical Lymphoma Myeloma & Leukemia

Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma

(2013) Driss Chaoui et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

(2013) Franck Morschhauser et al.   EUROPEAN JOURNAL OF CANCER

Strategies for Relapsed Peripheral T-Cell Lymphoma: The Tail That Wags the Curve

(2013) Matthew A. Lunning et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

(2013) Vivien Mak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

(2013) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences

(2012) Heather E. Eve et al.   BRITISH JOURNAL OF HAEMATOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

(2012) Gandhi Damaj et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project

(2012) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

(2012) Yuan Xiao Zhu et al.   LEUKEMIA & LYMPHOMA

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

(2011) T. E. Witzig et al.   ANNALS OF ONCOLOGY

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

(2011) Pier Luigi zinzani et al.   LEUKEMIA & LYMPHOMA

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

(2010) Greg Dueck et al.   CANCER

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

(2010) Christine I. Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis

(2010) Rachid Baz et al.   LEUKEMIA & LYMPHOMA

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

(2008) Peter H. Wiernik et al.   JOURNAL OF CLINICAL ONCOLOGY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY